Clinical trials: Respiratory Synctial Virus
COVID 19, Respiratory Synctial Virus
COMMUNITY - the COVID-19 Immunity Study
The principal aim of the COMMUNITY study is to investigate immune responses following SARS-CoV-2 infection and/or vaccination in healthcare workers and hospitalized COVID-19 patients.
- Conditions
- COVID 19, Respiratory Synctial Virus, Influenza Virus, SARS-CoV-2 Virus
- Trial name
- COMMUNITY (NCT06784739)
- Testing
- Blood sampling, Mucosal sampling, PCR-test
- Where
- 2 sites in Sweden
- Volunteers
- 2,420 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Respiratory Synctial Virus, COPD
Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study
The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD)…
- Conditions
- Respiratory Synctial Virus, COPD, Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD
- Trial name
- RECODE (NCT06735612)
- Where
- Spain
- Volunteers
- 716 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
Respiratory Synctial Virus, Asthma Childhood
Infant RSV Immunity Study
Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection.
- Trial name
- IRIS (NCT07653347)
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Respiratory Synctial Virus Infections
Phase 2 Study of the RSV/Flu-01E Vaccine Against Respiratory Syncytial Virus Infection in Older Adults
The aim of the study is to investigate immunogenicity and safety of the RSV/Flu-01E intranasal vaccine for the prevention of respiratory syncytial virus infection in volunteers over 60 years
- Trial name
- NCT06890429
- Testing
- RSV/Flu-01E
- Where
- 3 sites in Russia
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Research Institute of Influenza, Russia
Respiratory Synctial Virus Infections
Evaluation of the Effect of Nirsevimab on Hospitalizations Due to RSV Infection in Infants Under One Year of Age.
This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy.
- Trial name
- NCT06856967
- Testing
- Nirsevimab
- Where
- 8 sites in Italy
- Volunteers
- 138 people
- Sponsor
- Meyer Children's Hospital IRCCS
Respiratory Synctial Virus Infections
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in…
- Trial name
- NCT06775405
- Testing
- AK0529
- Where
- 18 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Respiratory Synctial Virus Infections
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults
The purpose of this first time in human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of 2 doses of the RSV investigational vaccine, when administered intramuscularly according to a 0, 1 month schedule…
- Trial name
- NCT02491463
- Testing
- GSK3389245A_LD GROUP, GSK3389245A_HD GROUP, Bexsero
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Synctial Virus
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
This is a randomized, observer-blind, irrelevant comparator-controlled trial in male and female subjects ≥24 months of age and <72 months of age.
- Trial name
- NCT02296463
- Testing
- RSV F Vaccine with adjuvant (0.5mL injection), RSV F Vaccine (0.5mL injection), Hepatitis A Vaccine (0.5mL injection)
- Where
- 4 sites in Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novavax